Fresenius Medical Care Corp (NYSE:FMS) is ranked as a Buy using the methodology of Louis Navellier for investing and his Portfolio Grader stock evaluator. This represents no change from the previous week and is the same ranking FMS has had from Portfolio Grader for 2 months.

The current recommendation of Buy for Fresenius Medical Care Corp (NYSE:FMS) is derived using the stock evaluator from Portfolio Grader, which incorporates Louis Navellier's investing approach. FMS has maintained this ranking for 2 months.

Fresenius Medical Care Corp (NYSE:FMS) is one of the 781 companies in the GICS Health Care sector, and a component of the 82 company Health Care Providers & Services GICS industry group within this sector. FMS has a market value of $30.3 billion which is in the top decile in its industry group. The ranking for FMS by Portfolio Grader places it 30 among the 82 companies in this industry group, placing it in the top half; in the top half of the sector with a ranking of 266 among the 781 companies in the sector, and number 1,593 in the nearly 5,000 company Portfolio Grader universe.

The current recommendation of Buy for Fresenius Medical Care Corp (NYSE:FMS) has been derived by using Louis Navellier's methodology for investing and his Portfolio Grader stock evaluator. This represents no change from the previous week and is the same ranking FMS has had from Portfolio Grader for the last month.

Currently, Fresenius Medical Care Corp (NYSE:FMS) has a Buy using Louis Navellier's approach to investing and his Portfolio Grader stock evaluator. The current Portfolio Grader recommendation on the shares has been in place for the last month.

Fresenius Medical Care Corp (NYSE:FMS) is a $29.7 billion in market value component of the Health Care Providers & Services GICS industry group where the ranking for FMS by Portfolio Grader places it 30 among the 82 companies in this industry group, giving it an above-average position. FMS is ranked in the top half of the sector with a ranking of 258 among the 785 companies in the sector and number 1,662 in the 5000 company Portfolio Grader company universe.

Currently, Fresenius Medical Care Corp (NYSE:FMS) has a Buy using the methodology of Louis Navellier for investing and his Portfolio Grader stock evaluator. FMS has recently seen its Portfolio Grader rating upgraded from a Hold to a Buy.

Fresenius Medical Care Corp (NYSE:FMS) ranks in the top 10% of its industry group, Health Care Providers & Services, and in the top decile of sector group, Health Care, with a market value of $30.0 billion. From an investment attractiveness prospective, FMS is ranked in the top quartile of the sector with a ranking of 169 among the 782 companies in the sector; the stock's Portfolio Grader ranking places it 20 among the 82 companies in this industry group, giving it a well above-average position and number 1,197 in the 5000 company Portfolio Grader company universe.

Fresenius Medical Care Corp (NYSE:FMS) ranks in the top decile in its industry group, Health Care Providers & Services, and in the top decile of sector group, Health Care, with a market value of $29.5 billion. From an investment attractiveness prospective, FMS is ranked in the top half of the sector with a ranking of 227 among the 783 companies in the sector; Portfolio Grader's current ranking for FMS puts it 24 among the 83 companies in this industry group, placing it in the top half and number 1,627 in the 5000 company Portfolio Grader company universe.

The current recommendation of Hold for Fresenius Medical Care Corp (NYSE:FMS) has been derived by using Louis Navellier's Portfolio Grader stock evaluator, which incorporates his investing methodology. FMS has maintained this ranking for 4 months.

The current recommendation of Hold for Fresenius Medical Care Corp (NYSE:FMS) has been derived by using Louis Navellier's Portfolio Grader stock evaluator, which incorporates his investing methodology. FMS has maintained this ranking for 4 months.